Published in Hepatitis Weekly, October 17th, 2005
The primary objective of the trial is to demonstrate the safety of Aethlon's Hemopurifier treatment technology. The secondary objective of the trial will be to obtain preliminary efficacy data related to serologic and virologic markers, including viral load measurements before and after treatment with the Hemopurifier.
Aethlon chairman and CEO, James A. Joyce, stated, "Five years ago, our vision that a device could capture circulating viruses and toxins was purely...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.